In a significant development, the Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC) has officially initiated a tender procedure for mRNA COVID-19 vaccines. Moderna, recognized as one of the two mRNA COVID-19 vaccines approved for use in Europe, alongside BioNTech-Pfizer’s vaccine, has enthusiastically welcomed this move and expressed its intent to actively participate in the tendering process.
HERA, established as a service of the EC, plays a pivotal role in fortifying Europe’s capacity to handle cross-border health emergencies effectively. The initiation of the tendering procedure is a strategic step towards securing a diversified portfolio of mRNA-based COVID-19 vaccines for Member States in 2024 and beyond.
Moderna’s commitment to advancing the fight against COVID-19 is underscored by its proactive engagement in the tender process. The company, having received approval for its mRNA COVID-19 vaccine, stands as a key player alongside BioNTech-Pfizer in contributing to Europe’s vaccination efforts.
Recognizing the importance of a diversified supply of mRNA COVID-19 vaccines, Moderna emphasizes the proven efficacy of mRNA technology in vaccine development. This platform has demonstrated flexibility in addressing the evolving nature of the pandemic, providing a robust response against current strains and offering adaptability for potential future variants of concern.
Moderna’s dedication to continuous improvement is evident in its updated COVID-19 vaccine for the 2023 vaccination season. This updated vaccine maintains its effectiveness against prevailing strains, including JN.1, showcasing the company’s commitment to staying ahead of the virus’s adaptive nature.
The company stresses the necessity for healthcare professionals and the public to have choices aligned with the latest scientific evidence. This flexibility is crucial for addressing the unique needs of diverse populations, especially the vulnerable, such as the elderly and immunocompromised individuals, contributing to the resilience of healthcare systems across the European Union.
With key stakeholders, including the European Medicines Agency, advocating for a diversified portfolio of COVID-19 vaccines, Moderna looks forward to the 2024 vaccination season. Adequate time for preparation is highlighted, considering expected recommendations from global health authorities and regulators regarding potential vaccine updates to address emerging variants.
While Moderna expresses optimism about the potential tender process, the company acknowledges the inherent uncertainties and risks involved. The forward-looking statement emphasizes the importance of not placing undue reliance on these statements due to the unpredictability of external factors that could impact actual results.
As the healthcare community eagerly anticipates the outcomes of this tender process, Moderna’s commitment to advancing mRNA technology for COVID-19 vaccines remains steadfast, contributing to the collective effort to overcome the challenges posed by the pandemic.
